The US Mycoplasma Testing Market development continues to gain momentum as biopharmaceutical production scales up nationwide. With cell therapy and gene therapy approvals increasing, the requirement for mycoplasma-free starting materials has become non-negotiable. Growing demand for point-of-release testing and in-process monitoring is compelling manufacturers to integrate testing into...